Targeting mTOR for cancer therapyCancer, Drug resistance, mTOR, Oncogene, Targeted therapyMechanistic target of rapamycin (mTOR) is a protein kinase regulating cell growth, survival, metabolism, and immunity. mTOR is usually assembled into several complexes such as mTOR complex 1/2......
Metabolic alterations in cancer can be driven by changes in signalling pathways involving kinases such as PI3K and mTOR, and transcription factors, including hypoxia inducible factor and MYC. These are important targets for cancer therapy in general and cancer metabolism in particular. Cancer cells inc...
Metabolic targets for cancer therapy Nat. Rev. Drug Discov., 12 (2013), pp. 829-846 Google Scholar Gandini et al., 2014 S. Gandini, M. Puntoni, B.M. Heckman-Stoddard, B.K. Dunn, L. Ford, A. DeCensi, E. Szabo Metformin and cancer risk and mortality: a systematic review and me...
As the presence of intra-tumoral T cells is a positive prognostic marker for cancer survival [63,119,120], tumor-specific T cells make the perfect “live drug” for cancer therapy. Lymphokine-activated killer (LAK) cells are one of the earliest cell types used in ACT, where peripheral ...
Immunotherapy is regarded as the most promising treatment for cancers. Various cancer immunotherapies, including adoptive cellular immunotherapy, tumor vaccines, antibodies, immune checkpoint inhibitors, and small-molecule inhibitors, have achieved certa
Inflammation has accompanied human beings since the emergence of wounds and infections. In the past decades, numerous efforts have been undertaken to explore the potential role of inflammation in cancer, from tumor development, invasion, and metastasis t
他是30多种学术期刊比如Molecular Cancer, BMC Cancer, Molecular Carcinogenesis, Cancer Biology and Therapy, Cancer Prevention Research的副编辑(associate editor), 高级编委(senior editor)或者编委 。担任超过90余种国际SCI期刊的审稿人和10...
mTOR: Mammalian target of rapamycin NADPH: Nicotinamide adenine dinucleotide phosphate NSCLC: Non-small cell lung cancer PDAC: Pancreatic ductal adenocarcinoma PDK1: Phosphoinositol-dependent kinase 1 PFS: Progression-free survival PI3K: Phosphatidylinositol 3-kinase PIP2: Phosphatidylinositol 4,5...
M. Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors. Breast Cancer Res. Treat. 125, 407–420 (2011). Article CAS PubMed Google Scholar Bordeira-Carrico, R., Pego, A. P., Santos, M. & Oliveira, C. Cancer syndromes and ...
Clinical evidence has linked cell metabolism with cancer outcomes. Together, these observations have raised interest in targeting metabolic enzymes for cancer therapy, but they have also raised concerns that these therapies would have unacceptable effects on normal cells. However, some of the first ...